RT Journal Article
SR Electronic
T1 Joint Vendor/User Approach to Stopper Selection
JF PDA Journal of Pharmaceutical Science and Technology
JO PDA J Pharm Sci Technol
FD Parenteral Drug Association (PDA)
SP 139
OP 144
VO 39
IS 3
A1 Farley, James J.
YR 1985
UL http://journal.pda.org/content/39/3/139.abstract
AB Much time, money and effort is spent in developing a new pharmaceutical preparation. It would be such a waste if there was some drug/package component interaction that prevented the medicine from being used. If insufficient planning is applied to the selection of the package components, such interactions can occur. In order to maximize the probability of having an “inert container” a proper amount of thought must be put into its selection. The communications flow to and from pharmaceutical firm marketing area, pharmaceutical firm research and development, supplier sales and supplier technical areas will be discussed along with the possible and recommended directions of flow along those information channels. The amount of information from customer to supplier and from supplier alone with the timing of the data will be discussed. While the Pharmaceutical Company does not want to make public too much of its closely guarded data, since it is the result of many years of research, it must volunteer enough so that the supplier can work together with the company to select the best package component, at the best cost in the shortest period of time. The rapport that is established enhances this. The items of information that should be given to the supplier so that the most appropriate component will be selected are recommended.